Literature DB >> 25823769

Evaluation of Mucosal Healing in Ulcerative Colitis by Fecal Calprotectin Vs. Fecal Immunochemical Test.

Shiho Takashima1, Jun Kato2, Sakiko Hiraoka1, Asuka Nakarai1, Daisuke Takei1, Toshihiro Inokuchi1, Yuusaku Sugihara1, Masahiro Takahara1, Keita Harada3, Hiroyuki Okada3, Takehiro Tanaka4, Kazuhide Yamamoto1.   

Abstract

OBJECTIVES: We previously showed that a quantitative fecal immunochemical test (FIT) can predict mucosal healing (MH) in ulcerative colitis (UC). Fecal calprotectin (Fcal) has also been reported as an important biomarker of UC activity. The aim of this study was to compare the predictive ability of these two fecal markers for MH in UC.
METHODS: FIT and Fcal were examined in stool samples from consecutive UC patients who underwent colonoscopy. Mucosal status was assessed via the Mayo endoscopic subscore (MES).
RESULTS: In total, 105 colonoscopies in 92 UC patients were evaluated in conjunction with the FIT and Fcal results. Both FIT and Fcal results were significantly correlated with MES (Spearman's rank correlation coefficient: 0.61 and 0.58, respectively). The sensitivity and specificity of the FIT values (<100 ng/ml) for predicting MH (MES 0 alone) were 0.95 and 0.62, respectively, whereas those of Fcal (<250 μg/g) were 0.82 and 0.62, respectively. The sensitivities became similar when MH was defined as MES 0 or 1 (0.86 vs. 0.86). Although the predictability of MH evaluated by the area under the receiver operating characteristics curve was similar for the two fecal markers (FIT 0.83 vs. Fcal 0.82 for MES 0 alone), the FIT results were relatively robust regardless of the cutoff value selected.
CONCLUSIONS: Both FIT and Fcal can efficiently predict MH in UC, but FIT appears to be more sensitive than Fcal for predicting MES 0 alone.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25823769     DOI: 10.1038/ajg.2015.66

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  25 in total

1.  Hemorrhoids detected at colonoscopy: an infrequent cause of false-positive fecal immunochemical test results.

Authors:  Sietze T van Turenhout; Frank A Oort; Jochim S Terhaar sive Droste; Veerle M H Coupé; Rene W van der Hulst; Ruud J Loffeld; Pieter Scholten; Annekatrien C T M Depla; Anneke A Bouman; Gerrit A Meijer; Chris J J Mulder; Leo G M van Rossum
Journal:  Gastrointest Endosc       Date:  2012-07       Impact factor: 9.427

2.  Prognosis of ulcerative colitis differs between patients with complete and partial mucosal healing, which can be predicted from the platelet count.

Authors:  Asuka Nakarai; Jun Kato; Sakiko Hiraoka; Toshihiro Inokuchi; Daisuke Takei; Yuki Moritou; Mitsuhiro Akita; Sakuma Takahashi; Keisuke Hori; Keita Harada; Hiroyuki Okada; Kazuhide Yamamoto
Journal:  World J Gastroenterol       Date:  2014-12-28       Impact factor: 5.742

3.  A new rapid quantitative test for fecal calprotectin predicts endoscopic activity in ulcerative colitis.

Authors:  Triana Lobatón; Francisco Rodríguez-Moranta; Alicia Lopez; Elena Sánchez; Lorena Rodríguez-Alonso; Jordi Guardiola
Journal:  Inflamm Bowel Dis       Date:  2013-04       Impact factor: 5.325

4.  Immunochemical fecal occult blood test is not suitable for diagnosis of hemorrhoids.

Authors:  H Nakama; N Kamijo; K Fujimori; A Horiuchi; S Abdul Fattah; B Zhang
Journal:  Am J Med       Date:  1997-06       Impact factor: 4.965

5.  Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.

Authors:  K W Schroeder; W J Tremaine; D M Ilstrup
Journal:  N Engl J Med       Date:  1987-12-24       Impact factor: 91.245

6.  The value of fecal calprotectin as a marker of intestinal inflammation in patients with ulcerative colitis.

Authors:  İbrahim Koral Önal; Yavuz Beyazit; Burçin Şener; Burak Savuk; Diğdem Özer Etık; Abdurrahim Sayilir; Erkin Öztaş; Serkan Torun; Yasemin Özderın Özın; Bilge Tunç Demırel; Aysel Ülker; Ülkü Dağli
Journal:  Turk J Gastroenterol       Date:  2012       Impact factor: 1.852

7.  Baseline faecal occult blood concentration as a predictor of incident colorectal neoplasia: longitudinal follow-up of a Taiwanese population-based colorectal cancer screening cohort.

Authors:  Li-Sheng Chen; Amy Ming-Fang Yen; Sherry Yueh-Hsia Chiu; Chao-Sheng Liao; Hsiu-Hsi Chen
Journal:  Lancet Oncol       Date:  2011-05-16       Impact factor: 41.316

8.  Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes.

Authors:  Alain M Schoepfer; Christoph Beglinger; Alex Straumann; Ekaterina Safroneeva; Yvonne Romero; David Armstrong; Carsten Schmidt; Michael Trummler; Valérie Pittet; Stephan R Vavricka
Journal:  Inflamm Bowel Dis       Date:  2013-02       Impact factor: 5.325

Review 9.  Importance of mucosal healing in ulcerative colitis.

Authors:  Gary R Lichtenstein; Paul Rutgeerts
Journal:  Inflamm Bowel Dis       Date:  2010-02       Impact factor: 5.325

10.  Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases.

Authors:  Stephane Nancey; Gilles Boschetti; Driffa Moussata; Eddy Cotte; Julie Peyras; Charlotte Cuerq; Julie Haybrard; Anne-Laure Charlois; Anne Mialon; Marion Chauvenet; Karine Stroeymeyt; Dominique Kaiserlian; Jocelyne Drai; Bernard Flourié
Journal:  Inflamm Bowel Dis       Date:  2013-04       Impact factor: 5.325

View more
  34 in total

1.  Fecal Calprotectin in Assessing Endoscopic and Histological Remission in Patients with Ulcerative Colitis.

Authors:  Wing Yan Mak; Anthony Buisson; Michael J Andersen; Donald Lei; Joel Pekow; Russell D Cohen; Stacy A Kahn; Bruno Pereira; David T Rubin
Journal:  Dig Dis Sci       Date:  2018-02-22       Impact factor: 3.199

Review 2.  Fecal calprotectin: its scope and utility in the management of inflammatory bowel disease.

Authors:  Shapur Ikhtaire; Mohammad Sharif Shajib; Walter Reinisch; Waliul Islam Khan
Journal:  J Gastroenterol       Date:  2016-02-20       Impact factor: 7.527

3.  Anti-TNF therapy and immunogenicity in inflammatory bowel diseases: a translational approach.

Authors:  Lívia Moreira Genaro; Luís Eduardo Miani Gomes; Ana Paula Menezes de Freitas Franceschini; Hugo Dugolin Ceccato; Rafael Nascimento de Jesus; Amanda Pereira Lima; Cristiane Kibune Nagasako; João José Fagundes; Maria de Lourdes Setsuko Ayrizono; Raquel Franco Leal
Journal:  Am J Transl Res       Date:  2021-12-15       Impact factor: 4.060

Review 4.  Utility of surrogate markers for the prediction of relapses in inflammatory bowel diseases.

Authors:  Jason Orlando Dimitri Musci; Jack Stephen Cornish; Jan Däbritz
Journal:  J Gastroenterol       Date:  2016-03-14       Impact factor: 7.527

Review 5.  Disease monitoring in inflammatory bowel disease.

Authors:  Shannon Chang; Lisa Malter; David Hudesman
Journal:  World J Gastroenterol       Date:  2015-10-28       Impact factor: 5.742

Review 6.  Evidence-based clinical practice guidelines for inflammatory bowel disease 2020.

Authors:  Hiroshi Nakase; Motoi Uchino; Shinichiro Shinzaki; Minoru Matsuura; Katsuyoshi Matsuoka; Taku Kobayashi; Masayuki Saruta; Fumihito Hirai; Keisuke Hata; Sakiko Hiraoka; Motohiro Esaki; Ken Sugimoto; Toshimitsu Fuji; Kenji Watanabe; Shiro Nakamura; Nagamu Inoue; Toshiyuki Itoh; Makoto Naganuma; Tadakazu Hisamatsu; Mamoru Watanabe; Hiroto Miwa; Nobuyuki Enomoto; Tooru Shimosegawa; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2021-04-22       Impact factor: 7.527

7.  Occult Blood in Feces Is Associated with Increased Risk of Psoriasis.

Authors:  Hyun Jung Lee; Kyungdo Han; Hosim Soh; Seong-Joon Koh; Jong Pil Im; Joo Sung Kim; Hyo Eun Park; Miri Kim
Journal:  Dermatology       Date:  2021-09-16       Impact factor: 5.197

Review 8.  Faecal Calprotectin in Assessment of Mucosal Healing in Adults with Inflammatory Bowel Disease: A Meta-Analysis.

Authors:  Mariusz A Bromke; Katarzyna Neubauer; Radosław Kempiński; Małgorzata Krzystek-Korpacka
Journal:  J Clin Med       Date:  2021-05-19       Impact factor: 4.241

9.  C-reactive protein is superior to fecal biomarkers for evaluating colon-wide active inflammation in ulcerative colitis.

Authors:  Natsuki Ishida; Tomohiro Higuchi; Takahiro Miyazu; Satoshi Tamura; Shinya Tani; Mihoko Yamade; Moriya Iwaizumi; Yasushi Hamaya; Satoshi Osawa; Takahisa Furuta; Ken Sugimoto
Journal:  Sci Rep       Date:  2021-06-14       Impact factor: 4.379

10.  Alternative diagnoses and demographics associated with a raised quantitative faecal immunochemical test in symptomatic patients.

Authors:  Mark S Johnstone; Gillian Miller; Grace Pang; Paul Burton; Georgios Kourounis; Jack Winter; Emilia Crighton; David Mansouri; Paul Witherspoon; Karen Smith; Stephen T McSorley
Journal:  Ann Clin Biochem       Date:  2022-03-03       Impact factor: 2.587

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.